Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Ultragenyx Pharmaceutical's Rebisufligene Etisparvovec?
Rebisufligene Etisparvovec is a gene therapy commercialized by Ultragenyx Pharmaceutical, with a leading Phase III program in Mucopolysaccharidosis III (MPS...